Skip to main navigation

>> Site Menu

Our Company
Our Science
- ABCD Platform
- Scientific Presentations
Focus Areas
Our Pipeline
Our Culture
- Join the Team
INVESTORS & MEDIA

Kodiak Sciences

>> Site Menu

Our Company
Our Science
Focus Areas
Our Pipeline
Our Culture
- Join the Team
INVESTORS & MEDIA

News Releases

> News - Sub Nav

Press Releases

News Releases

Year

September 28, 2026

Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria

Additional Formats

PDF Version

September 25, 2026

Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration

Additional Formats

PDF Version

August 13, 2026

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results

Additional Formats

PDF Version

August 10, 2026

Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema

Additional Formats

PDF Version

August 6, 2026

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026

Additional Formats

PDF Version

May 28, 2026

Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

Additional Formats

PDF Version

May 7, 2026

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

Additional Formats

PDF Version

May 1, 2026

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

Additional Formats

PDF Version

March 31, 2026

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Additional Formats

PDF Version

March 26, 2026

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Additional Formats

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12

Disclaimer

Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.

KODIAK SCIENCES INC.

1250 Page Mill Rd
Palo Alto, CA 94304
United States of America

Kodiak Sciences GMBH
Dammstrasse 19
6300 ZUG
Switzerland

info@kodiak.com

Kodiak Sciences Valais GMBH
Rottenstrasse 5
3930 VISP
Switzerland

LinkedIn Twitter

Copyright © 2026 Kodiak Sciences Inc.